RxDoctor Payments DataLook up a doctor →

Olurotimi Adekolu

Pulmonary Disease · New Haven, CTNPI 1073871372

Payments from drug & device makers

$14,736in general payments, 2019–2025

Across 676 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • AstraZeneca$3K
  • Harmony Biosciences LLC$892
  • Jazz Pharmaceuticals Inc.$804
  • Boehringer Ingelheim$523
  • Actelion Pharmaceuticals US, Inc.$486
  • plus $5K from 35 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK250$4,462
AstraZeneca106$2,645
Harmony Biosciences LLC35$892
Jazz Pharmaceuticals Inc.30$804
Boehringer Ingelheim25$523
Actelion Pharmaceuticals US, Inc.11$486
Regeneron Healthcare Solutions, Inc.22$465
Sanofi20$463
Takeda Pharmaceuticals U.S.A., Inc.19$454
Mallinckrodt Hospital Products Inc.15$454
Amgen21$390
Mylan Specialty L.p.24$375
Avadel CNS Pharmaceuticals, LLC13$286
Insmed, Inc.13$272
Verona Pharma, Inc.10$223
Portola Pharmaceuticals, LLC2$205
Genentech USA, Inc.8$165
Covis Pharma GmbH7$131
Baxter Healthcare5$103
Axsome Therapeutics, Inc.4$101
Inogen, Inc.4$91
Lilly USA, LLC3$87
Viatris Specialty LLC4$84
Sanofi-aventis U.S. LLC1$79
Philips North America LLC4$74
ZOLL Respicardia, Inc.1$54
AbbVie2$44
3b Medical, Inc.2$43
Azurity Pharmaceuticals, Inc.2$40
Pulmonx Corporation2$40
Watermark Medical, Inc.1$26
Advanced Respiratory, Inc1$22
Pfizer1$21
Vifor Pharma, Inc.1$20
United Therapeutics Corporation1$19
Merck1$17
Johnson & Johnson1$17
CSL Behring1$17
Eisai Inc.1$15
Shire North American Group Inc1$15
Novartis1$12

How this compares

$14,736 in reported general payments places this provider in the 80th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut →

Medicare billing

Part B allowed, 2024
$114,626
Medicare patients
361
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in New Haven

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →